Formosa Pharmaceuticals, Inc. has entered into an exclusive licensing agreement with Samil Pharmaceutical Co., Ltd. for the commercialisation of an ophthalmic drug in Vietnam.

• Therapeutic Indication: The agreement covers clobetasol propionate ophthalmic suspension 0.05% (APP13007) for the treatment of inflammation and pain following ocular surgery.
• Commercial Rights: Samil Pharmaceutical will hold exclusive rights to handle regulatory submissions and commercialisation of the product in Vietnam.
• Deal Structure: The agreement includes upfront payments, regulatory milestones, and royalties over the term of the licence.

This summary is based on a news report by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.